Large companies and mid-size companies increasingly depend on external innovation to find new sources of growth of competitiveness. How do big and mid-size MedTech companies handle early-stage investment opportunities and partnerships with start-ups and academic assets? How do these companies balance between collaboration, licensing, but also M&As, especially for bigger ones? Are there differences in their approach when dealing with early-stage assets? What criteria do they take account of when evaluating potential collaborations and licensing deals? As a result, what are the key steps in creating a start-up that is an attractive target for licensing or acquisition? What does this mean in terms of a financing plan for a start-up?
Moderator: Suzanne Elvidge, Freelance writer, Biopharma, Healthcare, Business 
